Tresiba (Insulin Degludec) is commonly used to provide continuous, long-term support for managing the chronic metabolic condition of Diabetes Mellitus (Type 1 and Type 2) in adults and children 1 year of age and older. Its therapeutic utility centers on establishing a foundational level of glucose control and stabilizing blood sugar patterns, providing support that helps ease the chronic burden of hyperglycemia.

The main therapeutic indications are the treatment of Type 1 diabetes and Type 2 diabetes, used to address chronically elevated blood sugar and glycemic variability. This consistency is important for patient comfort and managing the potential for low blood sugar, especially during sleep.

Therapeutic Focus and Patient Support

This medication is applied to address the persistent issue of chronically elevated blood sugar. It is used to help provide a constant background level of insulin, a necessary component of therapy that may support A1C management and assists in maintaining target glucose levels throughout the day. It provides therapeutic support by effectively addressing unstable fasting and overnight glucose levels, a common challenge for patients. The consistent action, lasting 42 hours or more, is used to address unpredictable swings in blood sugar, offering support that may assist in maintaining glycemic stability.

---

Quick Fact: Relief for Fasting Instability
Tresiba is relevant for managing unstable fasting and overnight glucose levels during periods without eating, contributing to easing the load of high glycemic variability.

Regulatory References

1. European Medicines Agency (EMA) overview

Who Can and Cannot Use Tresiba?

The official eligibility profile for Tresiba (Insulin Degludec) is defined by regulatory authorities and specifies the populations permitted and prohibited from using the medicine.

Eligibility Scope

Classification	Rule
Contraindicated	Use is prohibited during episodes of hypoglycemia (low blood sugar) or in patients with hypersensitivity to Insulin Degludec or any of the product's excipients.
Not Recommended	The medicine is not recommended for the treatment of diabetic ketoacidosis (DKA).

Population Eligibility Rules

Tresiba is indicated to improve glycemic control in adults and pediatric patients who are 1 year of age and older with Type 1 or Type 2 Diabetes Mellitus. Use is not established in children under 1 year of age.

Condition-Specific Eligibility:

Use is generally permitted in older adults (ge 65 years) and in patients with renal impairment or hepatic impairment. However, the regulatory label requires that glucose monitoring must be intensified for these populations.

Pregnancy and Lactation:

There is no available clinical data to establish the safety profile for use in pregnant women or during lactation.

Connection to the Overall Eligibility Profile

The regulatory documents establish mandatory contraindications (hypoglycemia, hypersensitivity) that prohibit use in specific clinical contexts. Otherwise, the medicine is approved for the adult and pediatric populations (aged ge 1 year). Restrictions apply to acute conditions like DKA and to special populations, such as those with organ impairment, who must adhere to the labeled requirement of intensified glucose monitoring.

Tresiba Interactions with other medicines and products

Official regulatory documents categorize interactions with Tresiba (insulin degludec) primarily through their effect on blood glucose control and specific co-administration risks. As a peptide, the product is not associated with documented pharmacokinetic interactions involving CYP enzymes or drug transporters.

Interaction Scope and Constraints

Classification	Official Regulatory Statement
Enhanced Glucose-Lowering Effect	Co-administration with agents such as ACE inhibitors, MAOIs, Salicylates, and other antidiabetic agents may increase the blood glucose-lowering action, raising the risk of hypoglycemia.
Reduced Glucose-Lowering Effect	Co-administration with medications like Corticosteroids, Diuretics, Sympathomimetic Agents, and Thyroid Hormones may decrease the blood glucose-lowering effect, increasing the risk of hyperglycemia.
Masking of Symptoms	Anti-adrenergic drugs, including beta-blockers, clonidine, and reserpine, may reduce or mask the warning signs of hypoglycemia.
Non-Glucose Pharmacodynamic Risk	Concomitant use with Thiazolidinediones (TZDs) is associated with a risk of dose-related fluid retention that may lead to or exacerbate heart failure.
Procedural Restrictions	The medicine must not be mixed or diluted with any other insulin or solution. It must also not be transferred from the pen into a syringe for administration due to the high risk of severe overdose.
Alcohol Interaction	Ingestion of alcohol is officially noted to increase the risk of hypoglycemia, although its overall effect on blood glucose can be variable.
Timing Constraint	If the product is administered outside of a consistent daily schedule, a minimum of eight hours must pass between injections.

Connection to the Official Interaction Profile

The regulatory interaction profile is primarily defined by numerous pharmacodynamic interactions that directly affect blood glucose balance, necessitating appropriate monitoring when co-administered. The profile also includes critical, specific warnings regarding the risk of heart failure with TZDs and explicit prohibitions against procedural deviations like mixing or using a syringe for administration, which are documented to prevent serious medication errors.

Tresiba, which is insulin degludec, is a soluble, ultra-long-acting basal insulin analog. Following subcutaneous injection, the formulation’s zinc and phenol rapidly diffuse, triggering the self-assembly of insulin degludec dihexamers into soluble, high-molecular-weight multi-hexamer chains. This process creates a stable, subcutaneous drug depot.

The protracted absorption profile is governed by the gradual dissociation of the multi-hexamer chains, which slowly release active insulin degludec monomers into the systemic circulation. These monomers function as agonists at the ubiquitous Insulin Receptor (IR), a cell surface tyrosine kinase. Binding of the monomer to the IR stimulates autophosphorylation of the beta-subunits, initiating intracellular signaling cascades, primarily through the PI3K-AKT pathway.

This downstream signaling promotes the translocation of Glucose Transporter 4 (GLUT4) vesicles to the plasma membrane in target cells, predominantly skeletal muscle and adipose tissue, thereby increasing glucose uptake. Concurrently, the activation modulates hepatic enzymes, resulting in the inhibition of hepatic glucose production (gluconeogenesis and glycogenolysis) and the inhibition of lipolysis in adipocytes. The net system-level consequence is a continuous, stable modulation of glucose homeostasis via peripheral uptake and centralized production suppression.

Administration Process

Tresiba is an injectable insulin glargine alternative administered subcutaneously. It is typically injected once daily into the thigh, upper arm, or abdomen. To maintain consistent absorption, it is recommended to rotate injection sites within the same body region for each dose.

Timing and Flexibility

This long-acting insulin provides a steady glucose-lowering effect over an extended period. While it is best administered at the same time each day to maintain a routine, the formulation allows for some flexibility in the timing of the dose when necessary, provided there is a minimum interval between injections.

Handling and Storage

Before use, the insulin should be checked to ensure the solution is clear and colorless. It should not be used if it appears cloudy or contains particles.

• Unused devices: Store in a refrigerator between 2°C and 8°C. Do not freeze.
• In-use devices: Once a pen or vial is in use, it can be kept at room temperature (below 30°C) or in the refrigerator for a specific number of weeks as defined by the product's shelf life. Always remove the needle after each injection to prevent contamination and leaking.

Delivery Systems

Tresiba is available in different delivery formats, including pre-filled disposable pens and vials. The delivery systems are designed to allow for dose increments, and the dose counter on the device shows the number of units selected. No manual conversion of the dose is required when selecting the amount on the dial.

Research Evidence / Overview of Studies for Tresiba (Insulin Degludec)

The clinical evaluation of Tresiba (insulin degludec) is supported by a regulator-reviewed body of research, primarily consisting of large-scale Randomized Controlled Trials (RCTs) and a dedicated long-term cardiovascular study. This evidence base provided the foundational research for the medicine’s use in the context of background blood sugar management.

---

Clinical Evidence for Type 1 and Type 2 Diabetes

These research studies were central to describing the medicine’s use in the context of foundational blood sugar management for both adults and children with Type 1 Diabetes (T1DM) and Type 2 Diabetes (T2DM). The studies monitored key biomarkers, such as long-term blood sugar control (measured by glycated hemoglobin, or HbA1c) and Fasting Plasma Glucose (FPG).

Studies compared insulin degludec against other established long-acting insulins. The resulting measurements of HbA1c levels generally aligned with the pre-defined target for non-inferiority when compared to the older basal insulins. Non-inferiority in this context refers to the observed change in the biomarker relative to the comparator. Research on dosing flexibility also explored outcomes of varying the daily injection time, involving a defined minimum time interval between doses.

---

Research on Glycemic Stability and Hypoglycemia

Comparative studies, known as the crossover studies (SWITCH trials), were conducted with patients considered to have a higher risk for hypoglycemic events, comparing insulin degludec directly against insulin glargine (U-100).

• Reported Hypoglycemia Rates: These studies reported patterns where a lower measured rate of nocturnal confirmed hypoglycemia was observed, as well as a lower measured rate of overall symptomatic hypoglycemia, compared to the comparator insulin. This research contributes to the broader evidence landscape regarding short-term changes in blood sugar control relative to other basal insulins.

---

Long-Term Cardiovascular Outcomes

A dedicated long-term cardiovascular study (DEVOTE trial) was conducted in over 7,500 adults with Type 2 Diabetes who already had established cardiovascular disease. The trial’s primary objective was to demonstrate non-inferiority for the composite outcome of Major Adverse Cardiovascular Events (MACE).

• Reported CV Findings: The trial reported that the MACE rate had MACE rates that were determined to satisfy the pre-defined criteria for non-inferiority when compared to the comparator basal insulin. Secondary analysis also reported patterns where a lower measured rate of severe hypoglycemia was observed with insulin degludec in this high-risk population.

---

Evidence in Specific Populations

• Pediatric Use: Research was evaluated in children and adolescents aged 1 year and older with Type 1 diabetes. These studies monitored HbA1c change and reported that the resulting measurements met the criteria for non-inferiority relative to the comparator in this age group.
• Older Adults: The main trials explored outcomes in patient subgroups, including those aged 65 years and older. Findings described patterns where measurements of HbA1c between these older adults and younger adults were observed to be generally consistent in the observed studies.

Key Studies & References Ultra-long-acting insulin degludec in the management of diabetes: clinical utility and future prospects (Review on Duration of Action)

Common questions about Tresiba (FAQ)

---

Q: Why do I have to rotate my injection site?

Official product information indicates that rotation of injection sites is necessary within the same chosen area (such as the abdomen, thigh, or upper arm). This practice is required to reduce the risk of developing lipodystrophy (skin thickening or pitting) and localized cutaneous amyloidosis, both of which can negatively affect how the insulin is absorbed.

---

Q: What types of medications may increase my risk of low blood sugar (hypoglycemia)?

According to regulatory documents, several medications may enhance the blood glucose-lowering effect of Tresiba, potentially increasing the risk of hypoglycemia (low blood sugar). Examples of these agents include ACE inhibitors, MAOIs (monoamine oxidase inhibitors), Salicylates, and other antidiabetic agents.

---

Q: Can I mix Tresiba with other insulins or dilute it?

Regulatory documents indicate that Tresiba should not be mixed or diluted with any other insulin or solution. Such actions could change the medicine's pharmacological properties. Furthermore, regulatory warnings state the insulin should not be transferred from the pen into a syringe for administration.

---

Q: What do the U-100 and U-200 strengths mean?

Tresiba is available in two concentrations: U-100 and U-200. The U-100 strength provides 100 units of insulin per milliliter of solution. The U-200 strength contains 200 units of insulin per milliliter, which allows individuals requiring larger basal doses to receive the unit amount in a smaller physical volume per injection.

---

Q: How is Tresiba different from other long-acting insulins?

Studies and official information show Tresiba is classified as an ultra-long-acting basal insulin analog. Its unique formation of stable structures under the skin results in a sustained absorption profile. This profile is intended to provide continuous, predictable background insulin coverage, which has been shown in studies to last for at least 42 hours.

---

Q: What do I do with the used needle after an injection?

Regulatory instructions detail that the used needle must be immediately unscrewed from the pen and placed into a dedicated, puncture-resistant sharps disposal container. The in-use pen has a shelf life of 8 weeks (56 days) and must be discarded after this time, even if it still contains insulin.

---

Q: What is the correct unit increment to dial on my Tresiba pen?

The pen's dosage increments vary by concentration. The U-100 FlexTouch pen allows dialing doses in 1-unit increments, up to 80 units. The U-200 FlexTouch pen allows dialing doses in 2-unit increments, up to a maximum dose of 160 units.

How to Store and Dispose of Tresiba® (Insulin Degludec)

Official regulatory guidelines define strict storage and disposal requirements for Tresiba to maintain product integrity and ensure safety.

Storage and Stability Requirements

Condition	Temperature and Duration	Protection Requirements
Unopened Pens	Store in a refrigerator at 2 C to 8 C (36 F to 46 F) until the expiration date.	Keep in the original carton to protect from light. Do not freeze.
Opened (In-Use) Pens	Store for a maximum of 8 weeks (56 days). May be kept at room temperature (up to 30 C or 86 F) or refrigerated.	Protect from light and excessive heat. Must be discarded after 8 weeks.

Handling and Disposal

Tresiba must never be frozen; discard the product if freezing is suspected. Do not share needles or the pen device with others. Used needles and syringes must be immediately placed into a dedicated, puncture-resistant sharps disposal container. Expired or unused pens and related waste should be disposed of in accordance with local environmental and pharmaceutical waste regulations.